GlaxoSmithKline to Sell Two Former Novartis Vaccines for up to EUR955 Million

Date : 10/21/2019 @ 8:12AM
Source : Dow Jones News
Stock : Glaxosmithkline Plc (GSK)
Quote : 1716.4  2.2 (0.13%) @ 4:35PM

GlaxoSmithKline to Sell Two Former Novartis Vaccines for up to EUR955 Million

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

1 Month : From Oct 2019 to Nov 2019

Click Here for more Glaxosmithkline Charts.
   By Ian Walker 
 

Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Monday that it is selling its rabies and tick-borne encephalitis vaccines to Bavarian Nordic AS (BAVA.KO) for up to 955 million euros ($1.07 billion).

Glaxo said the sale of the vaccines--which were bought as part of Novartis AG's (NOVN.EB) vaccine business in 2015--is in line with its plan to simplify the vaccines business.

Glaxo will receive an upfront payment of EUR301 million, milestone payments of EUR495 million and extra payments from inventory sales estimated at EUR159 million.

"This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our R&D pipeline, while also ensuring the continued supply of these important and successful vaccines," said Glaxo's President of Global Vaccines Roger Connor.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

October 21, 2019 03:57 ET (07:57 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.